Nuzenio

Therapeutics Reports

Therapeutics Reports news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Silence Therapeutics trial cuts phlebotomies to 0.2 per patient - Stock TitanStock Titan · Mon, 10 Aug 2026 11:33:40 GMTDenali Therapeutics Reports $3.6 Million in First-Quarter Revenue for Avlayah - geneonline.comgeneonline.com · Mon, 10 Aug 2026 11:30:09 GMTKaryopharm’s Aug. 13 results call will include slides online - Stock TitanStock Titan · Mon, 10 Aug 2026 11:30:00 GMTSilence Therapeutics (SLN) halves losses and funds operations into 2028 in Q2 update - Stock TitanStock Titan · Mon, 10 Aug 2026 11:26:59 GMTTenax Therapeutics reports Phase 3 LEVEL topline: missed primary but strong biomarker and subgroup signals - TradingViewTradingView · Mon, 10 Aug 2026 11:23:01 GMTApogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingViewTradingView · Mon, 10 Aug 2026 11:23:01 GMTSilence Therapeutics (SLN) halves net loss and boosts cash in Q2 2026 - Stock TitanStock Titan · Mon, 10 Aug 2026 11:20:49 GMTOruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 11:19:58 GMT

Timeline

Mon, 10 Aug 2026 11:33:40 GMTSilence Therapeutics trial cuts phlebotomies to 0.2 per patient - Stock Titan
Mon, 10 Aug 2026 11:30:09 GMTDenali Therapeutics Reports $3.6 Million in First-Quarter Revenue for Avlayah - geneonline.com
Mon, 10 Aug 2026 11:30:00 GMTKaryopharm’s Aug. 13 results call will include slides online - Stock Titan
Mon, 10 Aug 2026 11:26:59 GMTSilence Therapeutics (SLN) halves losses and funds operations into 2028 in Q2 update - Stock Titan
Mon, 10 Aug 2026 11:23:01 GMTTenax Therapeutics reports Phase 3 LEVEL topline: missed primary but strong biomarker and subgroup signals - TradingView
Mon, 10 Aug 2026 11:23:01 GMTApogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingView

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.PoliticsPolitics stories explain decisions, institutions, parties, leaders, laws, budgets, elections, courts, and public accountability.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Therapeutics Reports.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.